US20080032374A1 - Method for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum - Google Patents

Method for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum Download PDF

Info

Publication number
US20080032374A1
US20080032374A1 US10/579,690 US57969004A US2008032374A1 US 20080032374 A1 US20080032374 A1 US 20080032374A1 US 57969004 A US57969004 A US 57969004A US 2008032374 A1 US2008032374 A1 US 2008032374A1
Authority
US
United States
Prior art keywords
gene
fructose
bisphosphatase
microorganism
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/579,690
Other languages
English (en)
Inventor
Oskar Zelder
Corinna Klopprogge
Hartwig Schroder
Stefan Hafner
Burkhard Kroger
Patrick Kiefer
Elmar Heinzle
Christoph Wittmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Assigned to BASF AKTIENGESELLSCHAFT reassignment BASF AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KLOPPROGGE, CORINNA, HAFNER, STEFAN, SCHRODER, HARTWIG, ZELDER, OSKAR
Publication of US20080032374A1 publication Critical patent/US20080032374A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Definitions

  • Lysirme is used commercially as an animal feed supplement, because of its ability to improve the quality of feed by increasing the absorption of other amino acids, in human medicine, particularly as ingredients of infusion solutions, and in the pharmaceutical industry.
  • this lysine is principally done utilizing the grain positive Corynebacterium glutamicum, Brevibacterium flavunt and Brevibacterium lactofermentuwn (KIeemann, A., et. al., “Amino Acids,” in ULLMANN'S ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY, vol. A2, pp. 57-97, Weinham: VCH-Verlagsgesellschaft (1985)). These organisms presently account for the approximately 250,000 tons of lysine produced annually. A significant amount of research has gone into isolating mutant bacterial strains which produce larger amounts of lysine.
  • Microorganisms employed in microbial process for amino acid production are divided into 4 classes: wild-type strain, auxotrophic mutant, regulatory mutant and auxotrophic regulatory mutant (K. Nakayama et al., in Nutritional Improvement of Food and Feed Proteins, M. Friedman, ed., (1978), pp. 649-661).
  • Mutants of Corynebacterium and related organisms enable inexpensive production of amino acids from cheap carbon sources, e.g., molasses, acetic acid and ethanol, by direct fermentation.
  • the stereospecificity of the amino acids produced by fermentation makes the process advantageous compared with synthetic processes.
  • glucose Upon cellular absorption, glucose is phosphorylated with consumption of phosphoenolpyiuvate (phosphotransferase system) (Malin & Bourd, (1991) Journal of Applied Bacteriology 71, 517-523) and is then available to the cell as glucose-6-phosphate.
  • Sucrose Sucrose is converted into fructose and glucose-6-phosphate by a phosphotransferase system (Shio et al., (1990) Agricultural and Biological Chemistry 54, 1513-1519) and invertase reaction (Yamamoto et al., (1986) Journal of Fermentation Technology 64, 285-291).
  • glucose-6-phosphate dehydrogenase EC 1.1.14.9
  • glucose-6-phosphate isomerase EC 5.3.1.9
  • the enzyme glucose-6-phosphate isomerase catalyses the first reaction step off the Embden-Meyerhof-Parnas pathway, or glycolysis, namely conversion into fructose-6-phosphate.
  • the enzyme glucose-6-phosphate dehydrogenase catalyses the first reaction step of the oxidative portion of the pentose phosphate cycle, namely conversion into 6-phosphogluconolactone.
  • Pentose phosphates such as for exarmple 5-phosphoribosyl-1-pyrophosphate are required, for example, in nucleotide biosynthesis. 5-Phosphoribosyl-1-pyrophosphate is moreover a precursor for aromatic amino acids and the amino acid L-histidine.
  • NADPH acts as a reduction equivalent in numerous anabolic biosyntheses. Four molecules of NADPH are thus consumedafor the biosynthesis of one molecule of lysine from oxalacetic acid. Thus, carbon flux towards oxaloacetate (OAA) remain s constant regardless of system perturbations (J. Vallino et al., (1993) Biotechnol. Bioeng., 41, 633-646).
  • the present invention is based, at least in part, on the discovery of key enzyme-encodin genes, e.g., fructose-1,6-bisphosphatase, of the pentose phosphate pathway in Corynebacterium glutamicum, and the discovery that deregulation, e.g., increasing expression or activity of fructose-1,6-bisphosphatase results in increased lysine production. Furthermore, it has been found that increasing the carbon yield during production of lysine by deregulating, e.g., increasing, fructose-1,6 bisphosphatase expression or activity leads to increased lysine production.
  • the carbon source is fructose or sucrose. Accordingly, the present invention provides methods for increasing production of lysine by microorganisms, e.g., C. glutamicum, where fructose or sucrose is the substrate.
  • the invention provides methods for increasing metabolic flux through the pentose phosphate pathway in a microorganism comprising culturing amicroorganism comprising a gene which is deregulated under conditions such that metabolic flux through the pentose phosphate pathway is increased.
  • the microorganism is fermented to produce a fine chemical, e.g., lysine.
  • fructose or sucrose is used as a carbon source.
  • the gene is fructose-1,6-bisphosphatase.
  • the fructose-1,6-bisphosphatase gene is derived from Corynebacterium, e.g., Corynebacterium glutamicum.
  • fructose-1,6 bisphosphatase gene is overexpressed.
  • the protein encoded by the fructose-1,6-bisphosphatase gene has increased activity.
  • the microorganism further comprises one or more additional deregulated genes.
  • the one or more additional deregulated gene can include, but is not limited to, an ask gene, a dapA gene, an asd gene, a dapb gene, a ddh gene, a lysA gene, a lysE gene, a pycA gene, a zwf gene, a pepCL gene, a gap gene, a zwal gene, a tkt gene, a tad gene, a mqo gene, a tpi gene, a pgk gene, and a sigC gene.
  • the gene may be overexpressed or underexpressed.
  • the deregulated gene can encode a protein selected from the group consisting of a feed-back resistant as partokinase, a dihydrodipicolinate synthase, an aspartate semialdehyde dehydrogenase, a dihydrodipicolinate reductase, a diaminopimelate dehydrogenase, a diaminopimelate epimerase, a lysine exporter, a pyruvate carboxylase, a glucose-6-phosphate dehydrogenase, a phosphoenolpyruvate carboxylase, a glyceraldedyde-3-phosphate dehydrogenase, an RPF protein precursor, a transketolase, a transaldolase, a menaqurine oxidoreductase, a triosephosphate isomerase, a 3-phosphoglycerate kinase, and an RNA-polymerase sigma factor sigC.
  • the one or more additional deregulated genes can also include, but is not limited to, a pepCK gene, a mal E gene, a glgA gene, a pgi gene, a dead gene, a nienE gene, a citE gene, a mikE17 gene, a poxB gene, a zwa2 gene, and a sucC gene.
  • the expression of the at least one gene is upregulated, attenuated, decreased, downregulated or repressed.
  • the deregulated gene can encode a protein selected from the group consisting of a phosphoenolpyruvate carboxykinase, a malic enzyme, a glycogen synthase, a glucose-6-phosphate isomerase, an ATP. dependent RNA helicase, an o-succinylbenzoic acid-CoA ligase, a citrate lyase beta chain, a transcriptional regulator, a pyruvate dehydrogenase, an RPF protein precursor, and a Succinyl-CoA-Synthetase.
  • the protein has a decreased or an increased activity.
  • the microorganisms used in the methods of the invention belong to the genus Corynebacterium, e.g., Corynebacterium glutamicum.
  • the invention provides methods for producing a fine chemical comprising fermenting a microorganism in which fructose-1,6-bisphosphatase is deregulated and accumulating the fine chemical, e.g., lysine, in the medium or in the cells of the microorganisms, thereby producing a fine chemical.
  • the methods include recovenrng the fine chemical.
  • the fructose-1,6-bisphosphatase gene is overexpressed.
  • fructose or sucrose is used as a carbon source.
  • fuctose-1,6-bisphosphatase is derived from Corynebacterium glutamicum and comprises the nucleotide sequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:2.
  • FIG. 1 is a schematic representation of the pentose biosynthetic pathway.
  • FIG. 2 Comparison of relative mass isotopomer fractions of secreted lysine and trehalose measured by GC/MS in tracer experiments of Corynebacterium glutamicum ATCC 21526 during lysine production on glucose and fructose.
  • FIG. 3 In vivo carbon flux distribution in the central metabolism of Corynebacterium glutamicum ATCC -21526 during, lysine production on glucose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopboer modeling for 13 C tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively.
  • Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux reversibilities. All fluxes are expressed as a molar percentage of the mean specific glucose uptake rate (1.77 mmol g ⁇ 1 h ⁇ 1 ).
  • FIG. 4 In vivo carbon flux distribution in the central metabolism of Corynebacterium glutainicum ATCC 21526 during lysine production on fructose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopomer modeling for 13 C tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively.
  • Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux reversibilities. All fluxes are expressed as a molar percentage of the mean specific fructose uptake rate (1.93 mmol g ⁇ 1 h ⁇ 1 ).
  • FIG. 5 Metabolic network of the central metabolism for glucose-grown (A) and fructose-grown (B) lysine producing Corynebacterium glutamicum including transport fluxes, anabolic fluxes and fluxes between intermediary metabolite pools.
  • the present invention is based at least in part, on the identification of genes, e.g., Corynebacterium glutamicum genes, which encode essential enzymes of the pentose phosphate pathway.
  • the present invention features methods comprising manipulating the pentose phosphate biosynthetic paihway in a microorganism, e.g., Corynebacterium glutamicum such that the carbon yield is increased and certain desirable fine chemicals, e.g., lysine, are produced, e.g., produced-at increased yields.
  • the invention includes methods for producing fine chemicals, e.g., lysine, by fermentation of a microorganism, e.g., Corynebacterium glutamicum, having deregulated, e.g., increased, fructose-1,6-bisphosphatase, expression or activity.
  • a microorganism e.g., Corynebacterium glutamicum
  • fructose or sacdharose is used as a carbon source in the fermentation of the microorganism.
  • Fructose has been established to be a less efficient substrate for the production of fine chemicals, e. g., lysine, from microorganisms.
  • the present invention prbvides methods for optimizing production of lysine by microorganisms, e.g., C.
  • fructose or sucrose is the substrate.
  • Deregulation e.g., amplification, of fructose-1,6-bisphosphatase expression or activity leads to a higher flux through the pentose phosphate pathway, resulting in increased NADPH generation and increased lysine yield.
  • pentose phosphate pathway includes the pathway involving pentose phosphate enzymes (e.g., polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, e.g., lysine.
  • pentose phosphate pathway converts glucose molecules into biochemically useful smaller molecule.
  • pentose phosphosphate biosynthetic pathway includes the biosynthetic pathway involving pentose phosphate biosynthetic genes, enzymes (e.g., polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, e.g, lysine.
  • enzymes e.g., polypeptides encoded by biosynthetic enzyme-encoding genes
  • compounds e.g., precursors, substrates, intermediates or products
  • cofactors and the like utilized in the formation or synthesis of fine chemicals, e.g, lysine.
  • pentose phosphosphate biosynthetic pathway includes the biosynthetic pathway leading to the synthesis of fine chemicals, e.g., lysine, in a microorganisms (e.g., in vivo) as well as the biosynthetic pathway leading to the synthesis df fine chemicals, e.g., lysine, in vitro.
  • pentose phosphosphate biosynthetic pathway protein or “pentose phosphosphate biosynthetic pathway enzyme” includes a those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly or indirectly involved in the pentose phposphsphate biosynthetic pathway, e.g., the fructose-1,6-bisphosphatase enzyme.
  • pentose phosphosphate biosynthetic pathway gene includes a those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes which are directly or indirectly involved in the pentose phosphosphate biosynthetic pathway, e.g., the fructose-1,6-bisphosphatase gene.
  • amino acid-biosynthetic pathway gene is meant to include those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of amino acids, e.g., fructose-1,6-bisphosphatase. These genes may be identical to those which naturally occur within a host cell and are involved in the synthesis of any amino acid, and particularly lysine, within that host cell.
  • lysine biosynthetic pathway, gene includes those genes and genes fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of lysine, e.g., fructos-1,6-bisphosphatase. These genes can be identical to those which naturally occur within a host cell and are involved in the, synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such genes, for example, the genes can contain modifications or mutations which do not significantly affect the biological activity of the encoded protein.
  • the natural gene can be modified by mutagenesis or by introducing or substituting one or more nucleotides or by removing nonessential regions of the gene. Such modifications are readily performed by standard, techniques.
  • lysine biosynthetic pathway protein is meant to include those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly involved in the synthesis of lysine. These proteins can be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such proteins, for example, the proteins can contain modifications or mutations which do not significantly affect the biological activity of the protein. For example, the natural protein can be modified by mutagenesis or by introducing or substituting one or more amino acid, preferably by conservative amino acid substitution, or by removing nonessential regions of the protein. Such modifications are readily performed by standard techniques. Alternatively, lysine biosynthetic proteins can be heterologous to the particular host cell. Such proteins can be from any organism having genes encoding proteins having the same, or similar, biosynthetic roles.
  • carbon flux refers to the number of glucose molecules which proceed down a particular metabolic path relative to competing paths.
  • increased NADPH within a microorganism is achieved by altering the carbon flux distribution between the glycolytic and pentose phosphate pathways of that organism.
  • “Fructose-1,6-bisphosphatase activity” includes any activity exerted by a fructose-1,6-bisphosphatase protein, polypeptide or nucleic acid molecule as determined in vivo, or in vitro, according to standard techniques. Fructose-1,6-bisphosphatase is involved in many different metabolic pathways and found in most organisms. Preferably, a fructose-1,6-bisphosphatase acitivity includes the catalysis of the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate.
  • the ‘term fine, chemical’ is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries.
  • Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-protein 6 genic amino acids, pine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuiinaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, and referdnces contained therein), lipids, both saturated and unsaturated fatty acids.
  • Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms.
  • the term “amino acid” is art-recognized.
  • the proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weiheim (1985)).
  • Amino acids may be in the D- or L-optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins.
  • the ‘essential’ amino acids histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine
  • they are generally a nutritional requirement due to the complexity of their biosyntheses are readily converted by simple biosynthetic pathways to the remaining 11 ‘nonessential’ amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine).
  • Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.
  • Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine.
  • Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry.
  • Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/L-methionine are common feed additives. (Leuchtenberger, W. (1996) Amino aids—technical production and use, p. 466-502 in Rehm et al. (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim).
  • amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.
  • cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain ⁇ -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase.
  • Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway.
  • Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase.
  • Alanine, valine, and leucine are all biosynthetic products of pyruvte, the final product of glycolysis.
  • Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle.
  • Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate.
  • Isoleucine is formed from threonine.
  • a complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.
  • Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3 rd ed. Ch. 24: “Amino Acid Degradation and the Urea Cycle” p. 495-516 (1988)).
  • the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them.
  • amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L.
  • Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, “Vitamins” vol. A27, p. 443-613, VCH: Weinheim, 1996).
  • vitamin is art-recognized, and includes nutrients which are required by an organism for normal functionoing, but which that organism cannot synthesize by itself.
  • the group of vitamins may encompass cofactors and nutraceutical compounds.
  • cofactor includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic.
  • nutraceutical includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).
  • Thiamin (vitamin-B 1 ) is produced by the chemical coupling of pyrimidine and thiazole moieties.
  • Riboflavin (vitamin B 2 ) is synthesized from guanosine-5′-triphosphate (GTP) and ribose-5′-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).
  • vitamin B 6 The family of compounds collectively termed ‘vitamin B 6 ’(e.g., pyridoxine, pyridoxamine, pyridoxa-5′-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine.
  • Pantothenate pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)- ⁇ -alanine
  • pantothenate biosynthesis consist of the ATP-driven condensation of ⁇ -alanine and pantoic acid.
  • pantothenate The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to ⁇ -alanine and for the condensation to panthotenic acid are known.
  • the metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps.
  • Pantothenate, pyridoxal-5′-phosphate, cysteine and ATP are the precursors of Coenzyme A.
  • These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B 5 ), pantetheine (and its derivatives) and coenzyme A.
  • Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins.
  • Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the ⁇ -ketoglutarate dehydrogenase complex.
  • the folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin.
  • GTP guanosine-5′-triphosphate
  • L-glutamic acid L-glutamic acid
  • p-amino-benzoic acid The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5′-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.
  • Corrinoids such as the cobalamines and particularly vitamin B 12
  • porphyrines belong to a group of chemicals characterized by a tetrapyrole ring system.
  • the biosynthesis of vitamin B 12 is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known.
  • Nicotinic acid and nicotinamide are pyridine derivatives which are also termed ‘niacin’.
  • Niacin is the precursor of the important coenzymes NAD (nicotinamide and adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.
  • purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections.
  • the language “purine” or “pyrimidine” includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides.
  • the term “nucleotide” includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid.
  • the language “nucleoside” includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess.
  • nucleic acid molecules By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).
  • energy stores i.e., AMP
  • coenzymes i.e., FAD and NAD
  • purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and Related Compounds in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, p. 561-612).
  • enzymes involved in punine, pyrimidine, nucleoside, or nucledtide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.
  • Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5′-phosphate (IMP), resulting in the production of guanosine-5′-monophosphate (GMP) or adenosine-5′-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5′-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5′-triphosphate (CTP).
  • IMP inosine-5′-phosphate
  • AMP adenosine-5′-monophosphate
  • the deoxy-forms of all of these nucledtides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.
  • Trehalose consists of two glucose molecules, bound in ⁇ , ⁇ -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages: However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto et al., (1998) U.S. Pat. No. 5,759,610; Singer, M. A. and Lindquist, S. (1998) Trends Biotech. 16: 460-467; Paiva, C. L. A. and Panek, A. D. (1996) Biotech. Ann. Rev. 2: 293-314; and Shiosaka, M. (1997) J. Japan 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.
  • microorganisms e.g., recombinant microorganisms, preferably including vectors or genes (e.g., wild-type and/or mutated, genes) as described herein and/or cultured in a manner which results in the production of a desired fine chemical, e.g. lysine.
  • vectors or genes e.g., wild-type and/or mutated, genes
  • microorganism includes a microorganism (e.g., bacteria, yeast cell, fungal cell, etc.) which has been genetically altered, modified or engineered (e.g., genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (e.g., when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.
  • a microorganism e.g., bacteria, yeast cell, fungal cell, etc.
  • engineered e.g., genetically engineered
  • a “recombinant” microorganizm of the present invention has been genetically engineered such that it overexpresses at least one bacterial gene or gene product as described herein, preferably a biosynthetic enzyme encoding-gene, e.g., fructose-1,6-bisphosphatase, included within a recombinant vector as described herein and/or biosynthetic enzyme, e.g., fructose-1,6-bisphosphatase expressed from a recombinant vector.
  • a biosynthetic enzyme encoding-gene, e.g., fructose-1,6-bisphosphatase, included within a recombinant vector as described herein and/or biosynthetic enzyme, e.g., fructose-1,6-bisphosphatase expressed from a recombinant vector.
  • a microorganism expressing or overexpressing a gene product produces or overproduces the gene product as a result of expression or overexpression of nucleic acid sequences and/or genes encoding the gene product.
  • the recombinant microorganism has increased biosynthetic enzyme, e.g., fructose-1,6-bisphosphatase, activity.
  • At least one gene or protein may be deregulated, in addition to the fructose-1,6-bisphosphatase gene or enzyme, so as to enhance the production of L-amino acids.
  • a gene or an enzyme of the biosynthesis pathways for example, of glycolysis, of anaplerosis, of the citric acid cycle, of the pentose phosphate cycle, or of amino acids export may be deregulated.
  • a regulatory gene or protein may be deregulated.
  • expression of a gene may be increased so as to increase the intracellular activity or concentration of the protein encoded by the gene, thereby ultimately improving the production of the desired amino acid.
  • One skilled in the art may use various techniques to achieve the desired result. For example, a skilled practitioner may increase the number of copies of the gene or genes, use a potent promoter, and/or use a gene or allele which codes for the corresponding enzyme having high activity.
  • the activity or concentration of the corresponding protein can be increased by at least about 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400%, 500%, 1000% or 2000%, based on the starting activity or concentration.
  • the deregulated gene may include, but is not limited to, at least one of the following genes or proteins:
  • expression of a gene may be attenuated, decreased or repressed so as to decrease, for example, eliminate, the intracellular activity or concentration of the protein encoded by the gene, thereby ultimately improving the production of the desired amino acid.
  • a gene or allele that either codes for the corresponding enzyme having low activity or inactivates the corresponding gene or enzyme.
  • the activity or concentration of the corresponding protein can be reduced to about 0 to 50%, 0 to 25%, 0 to 10%, 0 to 9%, 0 to 8%, 0 to 7%, 0 to 6%, 0 to 5%, 0 to 4%, 0 to 3%, 0 to 2% or 0 to 1% of the activity or concentration of the wild-type protein.
  • the deregulated gene may include, but is not limited to, at least one of the following genes or proteins:
  • manipulated microorganism includes a microorganism that has been engineered (e.g., genetically engineered) or modified such that results in the disruption or alteration of a metabolic pathway so as to cause a change in the metabolism of carbon.
  • An enzyme is “overexpressed” in a metabolically engineered cell when the enzyme is expressed in the metabolically engineered cell at a level higher than the level at which it is expressed in a comparable wild-type cell. In cells that do not endogenously express a particular enzyme, any level of expression of that enzyme in the cell is deemed an “overexpression” of that enzyme for purposes of the present invention. Over expression may lead to increased activity of the protein encoded by the gene, e.g., fructose-1,6-bisphosphatase.
  • Modification or engineering of such microorganisms can be according to any methodology described herein including, but not limited to, deregulation of a biosynthetic pathway and/or overexpression of at least one biosynthetic enzyme.
  • a “manipulated” enzyme e.g., a “manipulated” biosynthetic enzyme
  • overexpressed or “overexpression” includes expression of a gene product (e.g., apentose phosphate biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • the microorganism can be genetically manipulated (e.g., genetically engineered) to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. Genetic manipulation,can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g.
  • modifying the chromosomal location of aparticular gene altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site or transcription terminator, increasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins).
  • modifying proteins e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like
  • the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.
  • a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.
  • deregulated includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified.
  • at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased, thereby enhancing or increasing the activity of the gene product.
  • the phrase “deregulated pathway” can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified.
  • apathway e.g., to simultaneously deregulate more than one gene in a given biosynthetic pathway
  • more than one enzyme e.g., two or three biosynthetic enzymes
  • operon includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more, preferably at least two, structural genes (e.g., genes encoding enzymes, for example, biosynthetic enzymes). Expression of the structural genes can be coordinately regulated, for example by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The structural genes can be transcribed to give a single mRNA that encodes all of the structural proteins. Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of each gene product encoded by the operon.
  • structural genes e.g., genes encoding enzymes, for example, biosynthetic enzymes.
  • Expression of the structural genes can be coordinately regulated, for example by regulatory proteins binding to the regulatory element or by anti-termination of transcription.
  • the structural genes can be transcribed to give a single mRNA that encodes all of the structural proteins. Due to the coordinated regulation
  • Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory. sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins).
  • Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.
  • a partcularly preferred “recombinant” microorganism of the present invention has been genetically engineered to overexpress a bacterially-derived gene or gene product.
  • bacterially-derived or “derived-from”, for example bacteria, includes a gene which is naturally found in bacteria or a gene product which is encoded by a bacterial gene (e.g., encoded by fructose-1,6-bisphosphatase).
  • the methodologies of the present invention feature recombinant microorganisms which overexpress one or more genes, e.g., the fructose-1,6-bisphosphatase, gene or have increased or enhanced the fructose-1,6-bisphosphatase activity.
  • a particularly preferred recombinant microorganism of the present invention e.g., Corynebacterium glutamicium, Corynebacterium acetoglutamicum, Coryebacterium acetoacidophilum, and Corynebacterium thermoaminogenes, etc.
  • a biosynthetic enzyme e.g. fructose-1,6-bisphosphatase, the amino acid sequence of SEQ ID NO:2 or encoded by the nucleic acid sequence of SEQ ID NO:1).
  • microorganism having a deregulated pentose phosphate pathway includes a microorganism having an alteration or modification in at least one gene encoding an enzyme of the pentose phosphate pathway or having an alteration or modification in an operon including more than one gene encoding an enzyme of the pentose phosphate pathway.
  • a preferred “microorganism having a deregulated pentose phosphate pathway” has been genetically engineered to overexpress a Cornynebacterium (e.g., C. glutamicium ) biosynthetic enzyme (e.g., has been engineered to overexpress fructose-1,6-bisphosphatase).
  • a recombinant microorganism is designed or engineered such that one or more pentose phosphate biosynthetic enzyme is overexpressed or deregulated.
  • a microorganism of the present invention overexpresses or is mutated for a gene or biosynthetic enzyme (e.g., a pentose phosphate biosynthetic enzyme) which is bacterially-derived.
  • a gene or biosynthetic enzyme e.g., a pentose phosphate biosynthetic enzyme
  • bacterially-derived or “derived-from”, for example bacteria, includes a gene product (e.g., fructose-1,6-bisphosphatase) which is encoded by a bacterial gene.
  • a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism).
  • the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of Bacillus, Brevibacterium, Cornyebacterium, Lactobacillus, Lactococci and Streptomyces.
  • the recombinant microorganism is of the genus Cornyebacterium.
  • the recombinant microorganism is selected from the group consisting of Cornynebacterium glutamicium, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum or Corynebacterium thermoaminogenes.
  • the recombinant microorganism is Cornynebacterium glutamicium.
  • An important aspect of the present invention involves culturing the recombinant microorganisms described herein, such that a desired compound (e.g., a desired fine chemical) is produced.
  • the term “culturing” includes maintaining and/or growing a living microorganism of the present invention (e.g. maintaining and/or growing a culture or strain).
  • a microorganism of the invention is cultured in liquid media.
  • a microorganism of the invention is cultured in solid media or semi-solid media.
  • a microorganism of the invention is cultured in media (e.g., a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism.
  • Carbon sources which may be used include sugars and carbohydrates, such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as for example soy oil, sunflower oil, peanut oil and, coconut oil, fatty acids, such as for example palmitic acid, stearic acid and linoleic acid, alcohols, such as for example glycerol and ethanol, and organic acids, such as for example acetic acid.
  • fructose or saccharose may be used individually or as a mixture.
  • Nitrogen sources which may be used comprise organic compounds containing nitrogen, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate.
  • the nitrogen sources may be used individually or as a mixture.
  • Phosphorus sources which may be used are phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding salts containing sodium.
  • the culture medium must furthermore contain metal salts, such as for example magnesium sulfate or iron sulfate, which are necessary for growth.
  • essential growth-promoting substances such as amino acids and vitamins may also be used in addition to the above-stated substances.
  • Suitable precursors may furthermore be added to the culture medium.
  • the stated feed substances may be added to the culture as a single batch or be fed appropriately during cultivation.
  • microorganisms of the present invention are cultured under controlled pH.
  • controlled pH includes any pH which results in production of the desired fine chemical, e.g., lysine.
  • microorganisms are cultured at a pH of about 7.
  • microorganisms are cultured at a pH of between 6.0 and 8.5.
  • the desired pH may be maintained by any number of methods known to those skilled in the art. For example, basic compounds such as sodium hydroxide, potassium hydroxide, ammonia, or ammonia water, or acidic compounds, such as phosphoric acid or sluic acid, are used to appropriately control the pH of the culture.
  • microorganisms of the present invention are cultured under controlled aeration.
  • controlled aeration includes sufficient aeration (e.g., oxygen) to result in production of the desired fine chemical, e.g., lysine.
  • aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media.
  • aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the growth vessel (e.g., fermentor) or by various pumping equipment.
  • Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the fermentation mixture).
  • microorganisms of the present invention are cultured without excess foaming (e.g., via addition of antifoaming agents such as fatty acid polyglycol esters).
  • microorganisms of the present invention can be cultured under controlled temperatures.
  • controlled temperature includes any temperature which results in production of the desired fine chemical, e.g., lysine.
  • controlled temperatures include temperatures between 15° C. and 95° C.
  • controlled temperatures include temperatures between 15° C. and 70° C.
  • Preferred temperatures are between 20° C. and 55° C., more preferably between 30° C. and 45° C. or between 30° C. and 50° C.
  • Microorganisms can be cultured (e.g., maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (e.g., rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation.
  • the microorganisms are cultured in shake flasks.
  • the microorganisms are cultured in a fermentor (e.g., a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous methods of fermentation.
  • batch process or “batch fermentation” refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death.
  • fed-batch process or “fed-batch” fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (e.g., added in increments or continuously) as the fermentation progresses.
  • continuous process or “continuous fermentation” refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or “conditioned” media is simultaneously removed, preferably for recovery of the desired fine chemical, e.g., lysine.
  • a defined fermentation media is added continuously to a fermentor and an equal amount of used or “conditioned” media is simultaneously removed, preferably for recovery of the desired fine chemical, e.g., lysine.
  • conditioned media e.g., lysine
  • culturing under conditions such that a desired fine chemical, e.g., lysine is produced includes maintaining and/or growing microorganisms under conditions (e.g., temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired fine chemical or to obtain desired yields of the particularifine chemical, e.g., lysine, being produced.
  • culturing is continued for a time sufficient to produce the desired amount of a fine chemical (e.g., lysine).
  • culturing is continued for a time sufficient to substantially reach maximal production of the fine chemical. In one embodiment, culturing is continued for about 12 to 24 hours.
  • culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours.
  • culturing is continued for a time sufficient to reach production yields of a fine chemical, for example, cells are cultured such that at least about 15 to 20 g/L of a fine chemical are produced, at least about 20 to 25 g/L of a fine chemical are produced, at least about 25 to 30 g/L of a fine chemical are produced, at least about 30 to 35 g/L of a fine chemical are produced, at least about 35 to 40 g/L of a fine chemical are produced, at least about 40 to 50 g/L of a fine chermical are produced, at least about 50 to 60 g/L of a fine chemical are produced, at least about 60 to 70 g/L of a fine chemical are produced, at least about 70 to 80 g/L of a fine chemical are produced, at least about
  • microorganisms are cultured under conditions such that a preferred yield of a fine chemical, for example, a yield within a range set forth above, is produced in about 24 hours, in about 36 hours, in about 40 hours, in about 48 hours, in about 72 hours, in about 96 hours, in about 108 hours, in about 122 hours, or in about 144 hours.
  • a preferred yield of a fine chemical for example, a yield within a range set forth above
  • the methodology of the present invention can further include a step of recovering a desired fine chemical, e.g., lysine.
  • a desired fine chemical e.g., lysine.
  • the term “recovering” a desired fine chemical, e.g., lysine includes, extracting, harvesting, isolating or purifying the compound from culture media.
  • Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (e.g., with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like.
  • a conventional resin e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.
  • a conventional adsorbent e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.
  • solvent extraction e.g.,
  • a fine chemical e.g., lysine
  • a fine chemical can be recovered from culture media by first removing the microorganisms from the culture. Media is then passed through or over a cation exchange resin to remove unwanted cations and then through or over an anion exchange resin to remove unwanted inorganic anions and organic acids having stronger acidities than the fine chemical of interest (e.g., lysine).
  • a desired fine chemical of the present invention is “extracted”, “isolated” or “purified” such that the resulting preparation is substantially free of other components (e.g., free of media components and/or fermentation byproducts).
  • the language “substantially free of other components” includes preparations of desired compound in which the compound is separated (e.g., purified or partially purified) from media components or fermentation byproducts of the culture from which it is produced.
  • the preparation has greater than about 80% (by dry weight) of the desired compound (e.g., less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (e.g., less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (e.g., less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (e.g., less than about 1-2% other media components or fermentation byproducts).
  • the desired compound e.g., less than about 20% of other media components or fermentation byproducts
  • more preferably greater than about 90% of the desired compound e.g., less than about 10% of other media components or fermentation byproducts
  • still more preferably greater than about 95% of the desired compound e.g., less than about 5% of other media components or fermentation byproducts
  • most preferably greater than about 98-99% desired compound e.g., less than about 1-2% other media components
  • the desired fine chemical e.g., lysine
  • the microorganism is biologically non-hazardous (e.g., safe).
  • the entire culture (or culture supernatant) can be used as a source of product (e.g., crude product).
  • the culture (or culture supernatant) supernatant is used without modification.
  • the culture (or culture supernatant) is concentrated.
  • the culture (or culture supernatant) is dried or lyophilized.
  • pentose phosphase pathway biosynthetic precursor includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase pentose phosphate biosynthesis.
  • the pentose phosphate biosynthetic precursor or precursor is glucose.
  • the pentose phosphate biosynthetic precursor is fructose.
  • the amount of glucose or fructose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (e.g., a concentration sufficient to enhance production of a fine chemical e.g., lysine).
  • Penitose phosphate biosynthetic precursors of the present invention can be added in:theform of a concentrated solution or suspension (e.g., in a suitable solvent such as water or buffer) or in the form of a solid (e.g., in the form of a powder).
  • pentose phosphate biosynthetic precursors of the present invention can be added as asingle aliquot, continuously or intermittently over a given period of time.
  • Providing pent,ose phosphate biosynthetic precursors in the pentose phosphate biosynthetic methodologies of the present invention can be associated with high costs, for example, when the methodologies are used to produce high yields of a fine chemical. Accordingly, preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes (e.g., at least one pentose phosphate biosynthetic enzyme) manipulated such that lysine or other desired fine chemicals are produced in a manner independent of precursor feed.
  • a manner independent of precursor feed when referring to a method for producing a desired compound includes an approach to or a mode of producing the desired compound that does not depend or rely on precursors being provided (e.g., fed) to the microorganism being utilized to produce the desired compound.
  • precursors being provided (e.g., fed) to the microorganism being utilized to produce the desired compound.
  • microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requning no feeding of the precursors glucose or fructose.
  • Alternative preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes manipulated such that L-Lysine or other fine chemicals are produced in a manner substantially independent of precursor feed.
  • a manner substantially independent of precursor feed includes an approach to or a method of producing the desired compound that depends or relies to a lesser extent on precursors being provided (e.g., fed) to the microorganism being utilized.
  • microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requiring feeding of substantially reduced amounts of the precursors glucose or fructose.
  • Preferred methods of producing desired fine chemicals in a manner independent of precursor feed or alternatively, in a manner substantially independent of precursor feed involve culturing microorganisms which have been manipulated (e.g., designed or engineered for example, genetically engineered) such that expression of at least one pentose phosphate biosynthetic enzyme is modified.
  • a microorganism is manipulated (e.g., designed or engineered) such that the production of at least one pentose phosphate biosynthetic enzyme is deregulated.
  • a microorganism is manipulated (e.g.
  • a microorganism is manipulated (e.g., designed or engineered) such that at least one pentose phosphate biosynthetic enzyme, e.g., fructose-1,6-bisphosphatase is overexpressed.
  • pentose phosphate biosynthetic enzyme e.g., fructose-1,6-bisphosphatase
  • a particularly preferred embodiment of the present invention is a high yield production method for producing a fine chemical, e.g., lysine, comprising culturing a manipulated microorganism under conditions such that lysine is produced at a significantly high yield.
  • the phrase “high yield production method”, for example, a high yield production method for producing a desired fine chemical, e.g. lysine includes a method that results in production of the desired fine chemical at a level which is elevated or above what is usual for comparable production methods.
  • a high yield production method results in production of the desired compound at a significaiitly high yield.
  • significantly high yield includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (e.g., production of the product at a commercially feasible cost).
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 2 g/L, 10 g/L, 15 g/L, 20 g/L, 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, or 200 g/L.
  • the invention firther features a high yield production method for producing a desied fine chemical, e.g., lysine, that involves culturing a manipulated microorganism under conditions such that a sufficiently elevated level of compound is produced within a commercially desirable period of time.
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 15-20 g/L in 5 hours.
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism .under conditions such that lysine is produced at a level.
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions suchi that lysine is produced at a level greater than 50-100 g/L in 20 hours.
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorgarusm under conditions such that lysine is produced at alevel greater than 140-160 g/L in 40 hours, for example greater than 150 g/L in 40 hours.
  • the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 130-160 g/L in 40 hours, for example, greater than 135, 145 or 150 g/L in 40 hours.
  • Values and ranges included and/or intermediate within the ranges set forth herein are also intended to be within the scope of the present invention.
  • lysine production at levels of at least 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, and 150 g/L in 40 hours are intended to be included within the range of 140-150 g/L in 40 hours.
  • ranges of 140-145 g/L or 145-150 g/L are intended to be included within the range of 140-150 g/L in 40 hours.
  • culturing a manipulated microorganism to achieve a production level of, for example, “140-150 g/L in 40 hours” includes culturing the microorganism for additional time periods (e.g., time periods longer than 40 hours), optionally resulting in even higher yields of lysine being produced.
  • Another aspect of the present invention features isolated nucleic acid molecules that encode proteins (e.g., C. glutamicium proteins), for example, Corynebactrium pentose phosphate biosynthetic enzymes (e.g., C. glutamicium pentose phosphate enzymes) for use in the methods of the invention.
  • proteins e.g., C. glutamicium proteins
  • Corynebactrium pentose phosphate biosynthetic enzymes e.g., C. glutamicium pentose phosphate enzymes
  • the isolated nucleic acid molecules used in the methods of the invention are fructose-1,6-bisphosphatase nucleic acid molecules.
  • nucleic acid molecule includes DNA molecules (e.g., linear, circular, cDNA or chromosomal DNA) and RNA molecules (e.g., tRNA, rRNA, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • isolated nucleic acid molecule includes a nucleic acid molecule which is free of sequences which naturally flank the nucleic acid molecule (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid molecule) in the chromnosomal DNA of the organism from which the nucleic acid is derived.
  • an isolated nucleic acid molecule can contain less than about 10 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the nucleic acid molecule in chromosomal DNA of the microorganism from which the nucleic acid molecule is derived.
  • an “isolated” nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular materials when produced by recombinant techiiques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • gene includes a nucleic acid molecule (e:g., a DNA molecule or segment thereof), for example, a protein or RNA-encoding nucleic acid mnolecule, that in an organism, is separated from another gene or other genes, by intergenic DNA (i.e., intervening or spacer DNA which naturally flanks the gene and/or separates genes inthe chromosomal DNA of the organism).
  • a gene may direct synthesis of an enzyme or. other protein molecule (e.g., may comprise coding sequences, for example, a contiguous, open reading frame (ORF) which encodes a protein) or may itself be functional in the organism.
  • ORF open reading frame
  • a gene in an organism may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. Individual genes contained within an operon may overlap without intergenic DNA between said individual genes.
  • An “isolated gene”, as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (i.e., is free of adjacent coding sequences which encode a second or distinct protein or RNA molecule, adjacent structural sequences or the like) and optionally includes 5′ and 3′ regulatory sequences, for example promoter sequences and/or terminator sequences.
  • an isolated gene includes predominantly coding sequences for a protein (e.g., sequences which encode Corynebactrium proteins).
  • an isolated gene includes coding sequences for a protein (e.g., for a Corynebactrium protein) and adjacent 5′ and/or 3′ regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (e.g., adjacent 5′ and/or 3′ Corynebactrium regulatory sequences).
  • an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.
  • the methods of the present invention features use of isolated fructose-1,6-bisphosphatate nucleic acid sequences or genes.
  • the nucleic acid or gene is derived from Bacillus (e.g., is Corynebacetrium -derived).
  • the term “derived from Corynebactrium ” or “ Corynebactrium -derived” includes a nucleic acid or gene which is naturally found in microorganisms of the genus Corynebactrium.
  • the nucleic acid or gene is derived from a microorganism selected fromithe group consisting of Cornyebacterium glutamicium, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum or Corynebacterium thermoaminogenes.
  • the nucleic acid or gene is derived from Corynebacterium glutamicium (e.g., is Cornynebacterium glutamicium -derived).
  • the nucleic acid or gene is a Cornynebacterium gene homologue (e.g., is derived from a species distinct from Cornynebacterium but having significant homology to a Cornynebacterium gene of the present invention, for example, a Cornynebacterium fructose-1,6-bisphosphatase gene).
  • bacterial-derived nucleic acid molecules or genes and/or Cornynebacterium -derived nucleic acid Molecules or genes e.g., Cornynebacterium -derived nucleic acid molecules or genes
  • the genes identified by the present inventors for example, Cornynebacterium or C. glutamicium fructose-1,6-bisphosphatase genes.
  • bacterial-derived nucleic acid molecules or genes and/or Cornynebacterium -derived nucleic acid molecules or genes e.g., C. glutamicium -derived nucleic acid molecules or genes
  • C. glutamicium -derived nucleic acid molecules or genes e.g., C.
  • an isolated nucleic acid molecule comprises the nucleotide sequences set forth as SEQ ID NO:1, or encodes the amino acid sequence set forth in SEQ ID NO:2.
  • an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 60-65%, preferably at least about 70-75%, more preferable at least about 80-85%, and even more preferably at least about 90-95% or more identical to a nucleotide sequence set forth as SEQ ID NO:1.
  • an isolated nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • a preferred, non-limiting example of stringent e.g.
  • hybridization conditions are hybridization in 6 ⁇ sodium chloride/sodium citrate (SSC) at about 45° C., folldowed by one or more washes in 0.2 ⁇ SSC, 0.1% SDS at 50-65° C.
  • SSC sodium chloride/sodium citrate
  • an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1 corresponds to a naturally-occurring nucleic acid molecule.
  • a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature.
  • a nucleic acid molecule of the present invention e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 can be isolated using standard molecular biology techniques and the sequence information provided herein.
  • nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2 nd, ed, Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory Press; Can Spring, Harbor, N.Y., 1989) or can be isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1.
  • a nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonuceotide primers according to standard PCR amplification techniques.
  • an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1.
  • an isolated nucleic acid molecule is or includes a fructose-1,6-bisphosphatase gene, or portion orfragment thereof.
  • an isolated fructose-1,6-bisphosphatase nucleic acid molecule or gene comprises the nucleotide sequence as set forth in SEQ ID NO:1 (e.g., comprises the C. glutamicium frucfose-1,6-bisphosphatase nucleotide sequence).
  • an isolated fructose-1,6-bisphosphatase nucleic acid molecule or gene comprises a nucleotide sequence that encodes the amino acid sequence as set forth in SEQ ID NO:2 (e.g., encodes the C.
  • an isolated fructose-1,6-bisphosphatase nucleic acid molecule or gene encodes a homologue of the fructose-1,6-bisphosphatase protein having the amino acid sequence of SEQ ID NO:2.
  • homologue includes a protein or polypeptide sharing at least about 30-35%, preferably at least about 35-40%, more preferably; at least about 40-50 %, and even more preferably at least about 60%, 70%, 80%, 90% or more identity with the amino acid sequence of a wild-type protein or pdlypeptide described herein and having a substantially equivalent functional or biological activity as said wild-type protein or polypeptide.
  • a fructose-1,6-bisphosphatase homologue shares at least about 30-35%, preferably at least about 35-40%, more preferably at least about 40-50 %, and even more preferably at least about 60%, 70%, 80%, 90% or more identity with the protein having the amino acid sequence set forth as SEQ ID NO:2 and has a substantially equivalent functional or biological activity (i.e., is a functional equivalent) of the protein having the amino acid sequence set forth as SEQ ID NO:2 (e.g., has a substantially equivalent pantothenate kinase activity).
  • an isolated fructose-1,6-bisphosphatase nucleic acid molecule or gene comprises a nucleotide sequence that encodes a polypeptide as set forth in SEQ ID NO:2.
  • an isolated fructose-1,6-bisphosphatase nucleic acid molecule hybridizes to all or a portion of a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or hybridizes to all or a portion of a nucleic acid molecule having a nucleotide sequence that encodes a polypeptide having the amino acid sequence of SEQ ID NOs:2.
  • hybridization conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions can be found in Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), chapters 7; 9 and 11.
  • a preferred, non-limiting example of stringent hybridization conditions includes hybridization in 4 ⁇ sodium chloride/sodium citrate (SSC), at about 65-70° C. (or hybridization in 4 ⁇ SSC plus 50% formamide at about 42-50° C.) followed by one or more washes in 1 ⁇ SSC, at about 65-70° C.
  • a preferred, non-limiting example of highly stringent hybridization conditions includes hybridization in 1 ⁇ SSC, at about 65-70° C. (or hybridization in 1 ⁇ SSC plus 50% formamide at about 42-50° C.) followed by one or more washes in 0.3 ⁇ SSC, at about 65-70° C.
  • a preferred, non-limiting example of reduced stringency hybridization conditions includes hybridization in 4 ⁇ SSC, at about 50-60° C. (or alternatively hybridization in 6 ⁇ SSC plus 50% formamide at about 40-45° C.) followed by one or more washes in 2 ⁇ SSC, at about 50-60° C. Ranges intermediate to the above-recited values, e.g., at 65-70° C. or at 42-50° C.
  • SSPE (1 ⁇ SSPE is 0.15 M NaCl, 10 mM NaH 2 PO 4 , and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1 ⁇ SSC is 0.15 M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete.
  • the hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10° C. less than the melting temperature (T m ) of the hybrid, where T m is determined according to the followimg equations.
  • T m (° C.) 2(#of A+T bases)+4(# of G+C bases).
  • additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, PVP and the like.
  • blocking agents e.g., BSA or salmon or herring sperm carrier DNA
  • detergents e.g., SDS
  • chelating agents e.g., EDTA
  • Ficoll e.g., Ficoll, PVP and the like.
  • an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH 2 PO 4 , 7% SDS at about 65° C., followed by one or more washes at 0.02M NaH 2 PO 4 , 1% SDS at 65° C., see e.g., Church and Gilbert (1984) Proc. Natl. Acad. Sci. USA 81:1991-1995, (or, alternatively, 0.2 ⁇ SSC, 1% SDS).
  • an isolated nucleic acid molecule comprises a nucleotide, sequence that is complementary to a fructose-1,6-bisphosphatase nucleotide sequence as set forth herein (e.g., is the full complement of the nucleotide sequence set forth as SEQ ID NO:1).
  • a nucleic acid molecle of the present invention can be isolated using standard molecular biology techniques and the sequence information provided herein.
  • nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual.
  • a nucleic acid of the invention e.g., a fructose-1,6-bisphosphatase nucleic acid molecule or gene
  • mutant fructose-1,6-bisphosphatase nucleic acid molecules or genes includes a nucleic acid molecule or gene having a nucleotide sequence which includes at least one alteration (e.g., substitution, insertion, deletion) such that the polypeptide or protein that may be encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene.
  • a mutant nucleic acid molecule or mutant gene encodes a polypeptide or protein having an increased activity (e.g., having an increased fructose-1,6-bisphosphatase activity) as compared to the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, for example, when assayed under similar conditions (e.g., assayed in microorganisms cultured at the same temperature).
  • a mutant gene also can have an increased level of production of the wild-type polypeptide.
  • an “increased or enhanced activity” or “increased or enhanced enzymatic activity” is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% more, more preferably at least 10-25% more and even more preferably at least 25-50%, 50-75% or 75-100% more than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values e.g., 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention.
  • Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein isolated or purified from a cell. Alternatively, an activity can be measured or assayed within a cell or in an extracellular medium.
  • a mutant nucleic acid or mutant gene (e.g., encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue, as described above, in that a mutant nucleic acid or mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or nucleic acid or producing said mutant protein or polypeptide (i.e., a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid or producing said mutant protein or polypeptide.
  • a protein honidlogue has an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (e.g., 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.
  • the present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include nucleic acid molecules and/or genes described herein (e.g., isolated nucleic acid molecules and/or genes), preferably Cornynebacterium genes, more preferably Cornynebacterium glutamicium genes, even more preferably Cornynebacterium glutamicium fructose-1,6-bisphosphatase genes.
  • nucleic acid molecules and/or genes described herein e.g., isolated nucleic acid molecules and/or genes
  • the present invention further features vectors (e.g., recombinant vectors) that include nucleic acid molecules (e.g., isolated or recombinant nucleic acid molecules and/or genes) described herein.
  • recombinant vectors are featured that include nucleic acid sequences that encode bacterial gene products as described herein, preferably Cornynebacterium gene products, more preferably Cornynebacterium glutamicium gene products (e.g., pentose phosphate enzymes, for example, fructose-1,6-bisphosphatase).
  • recombinant nucleic acid molecule includes, a nucleic acid molecule, (e.g., a DNA molecule) that has been altered modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides).
  • a recombinant nucleic acid molecule e.g., a recombinant DNA molecule
  • an isolated nucleic acid molecule or gene ofthe present invention e.g., an isolated fructose-1,6-bisphosphatase gene
  • recombinant vector includes a vector (e.g., plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains grelater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived.
  • a vector e.g., plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector
  • the recombinant vector includes a fructose-1,6-bisphosphatase gene or recombinant nucleic acid molecule including such fructose-1,6-bisphosphatase gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences andior artificial ribosome binding sites (RBSs).
  • regulatory sequences for example, promoter sequences, terminator sequences andior artificial ribosome binding sites (RBSs).
  • operably linked to regulatory sequence(s) means that the nucleotide sequence of the nucleic acid molecule or gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g., enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the nucleotide sequence, preferably expression of a gene product encoded by the nucleotide sequence (e.g., when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).
  • regulatory sequence includes nucleic acid sequences which affect (e.g., modulate or regulate) expression of other nucleic acid sequences.
  • a regulatory sequence is included in a recombinant nucleic acid molecule or recombinant vector in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, e.g., in a native position and/or orientation.
  • a gene of internest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (e.g., operably linked to “native” regulatory sequences, for example, to the “native” promoter).
  • a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to another (e.g., a different) gene in the natural organism.
  • a gene of interest can be included in a redombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence from another organism.
  • regulatory sequences from other microbes e.g., other bacterial regulatory sequences, bacteriophage regulatory sequences and the like
  • a regulatory sequence is a non-native or non-naturally-occurring sequence (e.g., a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized).
  • Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals and other expression control elements (e.g., sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA).
  • expression control elements e.g., sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA.
  • Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2 nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
  • Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (e.g., constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (e.g., inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (e.g., attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene, of interest is enhanced.
  • a recombinant nucleic acid molecule or recombinant vector of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a pentose phosphate biosynthetic enzyme, for example fructose-1,6-bisphosphatase) operably linked to a promoter or promoter sequence.
  • bacterial gene product e.g., a pentose phosphate biosynthetic enzyme, for example fructose-1,6-bisphosphatase
  • promoters of the present invention iniclude Corynebacterium promoters and/or bacteriophage promoters (e.g., bacteriophage which infect Corynebacterium ).
  • a promoter is a Corynebacterium promoter, preferably a strong Corynebacterium promoter (e.g., a promoter associated with a biochemical housekeeping gene in Corynebacterium or a promoter associated with a glycolytic pathway gene in Corynebacterium ).
  • a promoter is a bacteriophage promoter.
  • a recombinant nucleic acid molecule or recombinant vector of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences).
  • the term “terminator sequences” includes regulatory sequences which serve to terminate transcription of a gene. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (e.g., by adding structure to mRNA) for example, against nucleases.
  • a recombinant nucleic acid molecule or recombinant vector of the present invention includes sequences which allow for detection of the vector containing said sequences (i.e., detectable and/or selectable markers), for example, sequences that overcome auxotrophic mutations, for example, ura3 or ilvE, fluorescent markers, and/or colorimetric markers (e.g., lacZ/ ⁇ -galactosidase), and/or antibiotic resistance genes (e.g., amp or tet).
  • detectable and/or selectable markers for example, sequences that overcome auxotrophic mutations, for example, ura3 or ilvE, fluorescent markers, and/or colorimetric markers (e.g., lacZ/ ⁇ -galactosidase), and/or antibiotic resistance genes (e.g., amp or tet).
  • a recombinant vector of the present invention includes antibiotic resistance genes.
  • antibiotic resistance genes includes sequences which promote or confer resistance to antibiotics on the host organism (e.g., Bacillus ).
  • the antibiotic resistance genes are selected from the group consisting of cat (chloramphenicol resistance) genes, tet (tetracycline resistance) genes, erm (erythromycin resistance) genes, neo (neomycin resistance) genes and spec (spectinomycin resistance) genes.
  • Recombinant vectors of the present invention can fruther include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, amyE sequences can be used as homology targets for recombination into the host, chromosome.
  • proteins e.g. isolated pertose phosphate biosynthetic enzymes, for example isolated fructose-1,6-bisphosphatase.
  • proteins e.g., isolated pentose phosphate enzymes, for example isolated fructose-1,6-bisphosphatase
  • proteins are produced by recombinant DNA techniques and can be isolated from microorganisms of the present invention by an appropriate purification scheme using standard protein purification techniques.
  • proteins are synthesized chemically using standard peptide synthesis techniques.
  • an “isolated” or “purified” protein is substantially free of cellular material or other contaminating proteins from the microorganism from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • an isolated or purified protein ihas less than about 30% (by dry weight) of contaminatihg protein or chemicals, more preferably less than about 20% of contaminating protein or chemicals, still more preferably less than about 10% of contaminating protein or chemicals, and most preferably less than about 5% contaminating protein or chemicals.
  • the protein or gene product is derived from Cornynebacterium (e.g., is Cornynebacterium -derived).
  • the term “derived from Cornynebacterium ” or “ Cornynebacterium -derived” includes a protein or gene product which is encoded by a Cornynebacterium gene.
  • the gene product is derived from a microorganism selected from the group consisting of Cornynebacterium glutamicium, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum or Corynebacterium thermoaminogenes.
  • the protein or gene product is derived from Cornynebacterium glutamicium (e.g., is Cornynebacterium glutamicium -derived).
  • Cornynebacterium glutamicium e.g., is Cornynebacterium glutamicium -derived.
  • the term “derived from Cornynebacterium glutamicium ” or “ Cornynebacterium glutamicium -derived” includes a protein or gene product which is encoded by a Cornynebacterium glutamicium gene.
  • the protein or gene product is encoded by a Cornynebacterium gene homologue (e.g., a gene derived from a species distinct from Cornynebacterium but having significant homology to a Cornynebacterium gene of the present invention, for example, a Cornynebacterium fructose-1,6-bisphosphatase gene).
  • a Cornynebacterium gene homologue e.g., a gene derived from a species distinct from Cornynebacterium but having significant homology to a Cornynebacterium gene of the present invention, for example, a Cornynebacterium fructose-1,6-bisphosphatase gene.
  • bacterial-derived proteins or gene products and/or Cornynebacterium -derived proteins or gene products e.g., C. glutamicium -derived gene products
  • Cornynebacterium genes e.g., C. glutamicium genes
  • the genes identified by the present inventors for example, Cornynebacterium or C. glutamicium fructose-1,6-bisphosphatase genes.
  • bacterial-derived proteins or gene products and/or Cornynebacterium -derived proteins or gene products e.g., C.
  • glutamicium -derived gene products that are encoded bacterial and/or Cornynebacterium genes (e.g., C. glutamicium genes) which differ from naturally-occurring bacterial and/or Cornynebacterium genes (e.g., C. glutamicium genes), for example, genes which have nucleic acids that are mutated, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention.
  • C. glutamicium genes genes which have nucleic acids that are mutated, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention.
  • mutate e.g., substitute
  • an isolated protein of the present invention e.g., an isolated pentose phosphate biosynthetic enzyme, for example isolated fructose-1,6-bisphosphatase
  • an isolated protein of the present invention has an amino acid sequence shown in SEQ ID NO:2.
  • an isolated protein of the present invention is a homologue of the protein set forth as SEQ ID NO:2, (e.g., comprises an amino acid sequence at least about 30-40% identical, preferably about 40-50% identical, more preferably about 50-60% identical, and even more preferably about 60-70%, 70-80%, 80-90%, 90-95% or more identical to the amino acid sequence of SEQ ID NO:2, and has an activity that is substantially similar to that of the protein encoded by the amino acid sequence of SEQ ID NO:2.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
  • gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence.
  • the comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm.
  • a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77.
  • Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul et al. (1990) J. Mol. Biol. 215:403-10.
  • Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Research 25(17):3389-3402.
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • the percent homology between two amino acid sequences can be determined using the GAP program in the GCG software package:(available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4.
  • the percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package (available at http://www.gcg.com), using a gap weight of 50 and a length weight of 3.
  • Corynebacterium glutamicum ATCC 21526 was obtained from the American Type and Culture Collection Manassas, USA). This homoserine auxptrophic strain excretes lysine during L-threonine limitation due to the bypass of concerted aspartate kinase inhibition.
  • Precultures were grown in complex medium containing 5 g L ⁇ 1 of either fructose or glucose.
  • the complex medium was additionally amended with 12 g L ⁇ 1 agar.
  • a minimal medium amended with 1 mg ml ⁇ 1 calcium panthotenate HCl was used (Wittmann, C. and E.
  • Precultivation consisted of three steps involving (i) a starter cultivation in complex medium with cells from agar plate as inoculum, (ii) a short cultivation for adaption to minimal medium, and (iii) a prolonged cultivaion on minimal medium with elevated concentrations of essential amino acids.
  • Pre-cultures inoculated from agar plates were grown overnight in 100 ml baffled shake flasks on 10 ml complex medium. Afterwards cells were harvested by centrifugation (8800 g, 2 min, 30° C.), inoculated into minimal medium, and grown-up to an optical density of 2 to obtain exponentially growing cells adapted to minimal medium.
  • cells were harvested by centrifugation (8800 g, 30° C., and 2 min) including a washing step with sterile 0.9% NaCl. They were then inoculated into 6 ml minimal medium in 50 ml baffled shake flasks with initial concentrations of 0.30 g L ⁇ 1 threonine, 0.08 g L ⁇ 1 methionine, 0.20 g L ⁇ 1 leucine, and 0.57 g L ⁇ 1 citrate. As carbon source 70 mM glucose or 80 mM fructose were added, respectively. Cells were grown until depletion of the essential amino acids, which was checked by HPLC analysis.
  • Cell concentration was determined by measurement of cell density at 660 nm (OD 660 nm) using a photometer (Marsha Pharmacia biotech, Freiburg, Germany) or by gravimetry. The latter was determined by harvesting 100 ml of cells from cultivation broth at room temperature for 10 min at 3700 g, including a washing step with water. Washed cells were dried at 80° C. until weight constancy. The correlation factor (g biomass/OD 660nm ) between dry cell dry mass and OD 660nm was determined as 0.353.
  • HP 6890 gas chromatograph Hewlett Packard, Palo Alto, USA
  • HP 5MS column 5% phenyl-methyl-siloxane-diphenyldimnethylpolysiloxane, 30 m ⁇ 250 ⁇ m, Hewlett Packard, Paolo Alto, Calif., USA
  • a quadrupole mass selective detector with electron impact ionizatiori at 70 eV was applied.
  • Sample preparation included lyophilization of the culture supernatant, dissolution in pyridine, and subsequent two-step derivatization of the sugars with hydroxylamine and (trimethylsilyl)trifluoroacetamide (BSTFA) Macherey & Nagel, Düren, Germany) (13, 14).
  • BSTFA trimethylsilyl)trifluoroacetamide
  • ⁇ -D-ribose was used as internal standard for quantification.
  • the injected sample volume was 0.2 ⁇ l.
  • the time program for GC analysis was as follows: 150° C. (0-5 min), 8° C. min ⁇ 1 (5-25 min), 310° C. (25-35 min). Helium was used as carrier gas with a flow of 1.5 1 min ⁇ 1 .
  • the inlet temperature was 310° C. and the detector temperature was 320° C.
  • Acetate, lactate, pyruvate, 2-oxoglutarate, and dihydroxyacetone were determined by BPLC utilizing an Aminex-HPX-87H Biorad Column (300 ⁇ 7.8 mm, Hercules, Calif., USA) with 4 mM sulfuric acid as mobile phase at a flow rate of 0.8 ml min ⁇ 1 , and UV-detection at 210 nm.
  • Glycerol was quantified by enzymatic measurement (Boehringer, Mannheim, Germany).
  • Amino acids were analyzed by HPLC (Agilent Technologies, Waldbronn, Germany) utilizing a Zorbax Eclypse-AAA column (150 ⁇ 4.6 mm, 5 ⁇ m, Agilent Technologies, Waldbronn Germany), with automated online derivatization (o-phtaldialdehyde +3-mercaptopropionic acid) at a flow rate of 2 ml min ⁇ 1 , and fluorescence detection. Details are given in the instruction manual ⁇ -amino butyrate was used as internal standard for quantification.
  • Quantification of mass isotopomer distributions was performed in selective ion monitoring (SIM) mode for the ion cluster m/z 431-437.
  • This ion cluster corresponds to a fragment ion, which is formed by loss of a t-butyl group from the derivatization residue, and thus includes the complete carbon skeleton of lysine (Wittmann, C., M. Hans and E. Heinzle. 2002. Analytical Biochem. 307:379-382).
  • the labeling pattern of trehalose was determined from its trnethylsilyl (TMS) derivate as described previously (Wittmann, C., H. M. Kim and E. Heinzle 2003.
  • the labeling pattern of trehalose was estimated via the ion cluster at m/z 361-367 corresponding to a fragment ion that contained an entire monomer unit of trehalose and thus a carbon skeleton equal to that of glucose 6-phosphate. All samples were measured first in scan mode therewith excluding isobaric interference between analyzed products and other sample components. All measurements by SIM were performed in duplicate.
  • Metabolic modelling and parameter estimation All metabolic simulations were carried out on a personal computer. Metabolic network of lysine-producing C. glutamicum was implemented in Matlab 6.1 and Simulink 3.0 (Mathworks, Inc., Natick, Mass. USA). The software implementation included an isotopomer model in Simulink to calculate the 13 C labeling distribution in the network. For parameter estimation the isotopomer model was coupled with an iterative optiniation algorithm in Matlab. Details on the applied computational:tools are given by Wittmann and Heinzle (Wittmann, C. and E. Heinzle 2002 Appl. Environ. Microbiol. 68:5843-5859).
  • the metabolic network was based on previous work and comprised glycolysis, pentose phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, anaplerotic carboxylation of pyruvate, biosynthesis of lysine and other secreted products (Tab. 1), and anabolic fluxes from intermediary precursors into biomass.
  • PPP pentose phosphate pathway
  • TCA tricarboxylic acid
  • Tab. 1 biosynthesis of lysine and other secreted products
  • anabolic fluxes from intermediary precursors into biomass In addition uptake systems for glucose and fructose were alternatively implemented. Uptake of glucose involved phosphorylation to glucose 6-phosphate via a PTS (Ohnishi, J., S. Mitsuhashi, M. Hayashi, S. Ando, H. Yokoi, K. Ochiai and M. A. Ikeda 2002 Appl. Microbiol.
  • the measured labeling of lysine and trehalose was not sensitive towards (i) the reversibility of the flux between the lumped pools of phosphoenolpyruvate/pyruvate and malate/oxaloacetate and (ii) the reversibility of malate dehydrogenase and fumarate hydratase in the TCA cycle. Accordingly these reactions were regarded irreversible.
  • the labeling of alanine from a mixture of naturally labeled and [ 13 C 6 ] labeled substrate which is sensitive for these flux parameters, was not available in this study. Based on previous results the glyoxylate pathway was assumed to be inactive (Wittmann, C. and E. Heinzle 2002 Appl. Environ. Microbiol. 68:5843-5859).
  • Metabolic fluxes of lysine producing C. glutamicum were analyzed in comparative batch cultures on glucose and fructose. For this purpose pre-grown cells were transferred into tracer medium and incubated for about 5 hours. The analysis of substrates and products at the beginning and the end of the tracer experiment revealed drastic differences between the two carbon sources. Overall 11.1 mM lysine was produced on glucose, whereas a lower concentration of only 8.6 mM was reached on fructose. During the incubation over 5 hours, the cell concentration increased from 3.9 g L-1 to 6.0 g L ⁇ 1 (glucose) and from 3.5 g L-1 to 4.4 g, L-1 (fructose).
  • Relative mass isotopomer fractions of secreted lysine and trehalose were quantified with GC-MS. These-mass isotoppmer fractions are sensitive towards intracellular fluxes and therefore display fingerprints for the fluxome of the investigated biological system.
  • labeling patterns of secreted lysine and trehalose differed, significantly between glucose and fructose-grown cells of C. gluiamicum. The differences were found for both applied tracer labelings and for both measured products. This indicates substantial differences in the carbon flux pattern depending on the applied carbon source.
  • M 0 denotes the relative amount of non-labelled mass isotopomer fraction
  • M 1 the relative amount of the single labelled mass isotopomer fraction
  • corresponding terms stand for higher labelling Lysine (on [1- 13 C] Trehalose (on [1- 13 C] Trehalose (on 50% [ 13 C 6 ] labeled substrate) labeled substrate) labeled substrate)
  • FIGS. ( 4 , 5 ) The obtained infracellular flux distributions for lysine-producing C. glutamicum on glucose and fructose are shown in FIGS. ( 4 , 5 ).
  • the intracellular fluxes differed tremendously depending on the carbon source applied.
  • 62% of the carbon flux was directed towards the PPP, whereas only 36% were channeled through the glycolytic chain ( FIG. 4 ) Due to this a relatively high amount, 124% NADPH was generated by the PPP enzymes glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase.
  • the situation on fructose was completely different ( FIG. 5 ).
  • the performed flux analysis revealed the in vivo activity of two PTS for uptake of fructose, whereby 92.3% of fructose were taken up by fructose specific PTS Fructose . A comparably small fraction of 7.7% of fructose was taken up by PTS Mannose .
  • the majority of fructose entered the glycolysis at the level of fructose 1,6-bisphosphatase, whereas only a small fraction was channeled upstream at fructose 6-phosphate into the glycolytic chain.
  • the PPP exhibited a dramatically reduced activity of only 14.4%.
  • Glucose 6-phosphate isomerase operated in opposite directions on the two carbon sources. In glucose-grown cells 36.2% net flux were directed from glucose 6-phosphate to fructose 6-phosphate, whereas a backward net flux of 1:5.2% was observed on fructose.
  • fructose On fructose, the flux through glucose 6-phosphate isomerase and PPP was about twice as high as the flux through the PTS Mannose . However this was not due to a gluconeogenetic flux of carbon from fructose-1,6-bisphosphatase to fructose 6-phosphate, which could have supplied extra carbon flux towards the PPP. In fact flux through fructose 1,6-bisphosphatase catalyzing this reaction was zero.
  • the metabolic reactions responsible for the additional flux towards the PPP are the reversible enzymes transaldolase and transketolasein the PPP. About 3.5% of this additional flux was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway. Moreover 4.2% of flux was directed towards fructose 6-phosphate and the PPP by the action of transaldolase.
  • glutamicum possesses an operating meitabolic cycle via fructose 6-phosphate, glucose 6-phosphate, and ribose 5-phosphate. Additional flux into the PPP was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway, and by the action of transaldolase, which redirected glyceraldehyde 3-phosphate back into the PPP, thus bypassing gluconeogenesis. This cycling activity may help the cell to overcome NADPH limitation on fructose. The drastically reduced flux arriving at glucose 6-phosphate for fructose-grown C. glutamicum might also explain the reduced formation of trehalose on this substrate (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind.
  • Glucose. 6-phosphate isomerase operated in opposite directions depending on the carbon source. In glucose-grown net flux was directed from glucose 6-phosphate to fructose 6-phosphate, whereas an inverse net flux, was observed on fructose. This underlines the importance of the reversibility of this enzyme for metabolic flexibility in C. glutamicum.
  • the following calculations provide a comparison of the NADPH metabolism of lysine producing C. glutamicum on fructose and glucose.
  • the overall supply of NADPH. was calculated from the estimated flux through glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and isocitrate dehydrogenase.
  • glucose 6-phosphate dehydrogenase (62.0%)
  • glucose 6-phosphate dehydrogenase (62.0%) supplied the major fraction of NADPH.
  • Isocitrate dehydrogenase. (52.9%) contributed only to a minor extent.
  • the reduction of dihydroxyacetone to glycerol could additionally be favored:by the high NADH/NAD ratio and thus contribute to regeneration of excess NADH.
  • the NADH demanding lactate formation from pyruvate could have a similar background as the production of glycerol.
  • NADH excess under lysine producing conditions characterized by relatively high TCA cycle activity and reduced biomass yield, might be even higher.
  • fructose 1,6-bisphosphatase during growth on fructose is detrimental from the viewpoint of lysine production but not surprising, because this gluconeogenetic enzyme is not required during growth on sugars and probably suppressed. In prokaryotes, this enzyme is under efficient metabolic control by e.g. fructose 1,6-bisphosphatase, fructose-2,6-bisphosphatase, metal ions and AMP (Skrypal, I. G. and O. V. Iastrebova. 2002. Miobiol Z. 64:82-94). It is known that C. glutamicum can grow on acetate (Wendisch, V. F., A. A. de Graaf, H. Sahm H.
  • Another bottleneck comprises the strong secretion of dihydroxyacetone, glycerol, and lactate.
  • the formation of dihydroxyacetone and glycerol could be blocked by deregulation, e.g., deletion of the corresponding enzymes.
  • the conversion of dihydroxyacetone phosphate to dihydroxyacetone could be catalyzed by a corresponding phosphatase.
  • a dihydroxyacetone phosphatase has however yet not been annotated in C. glutamicum (see the National Center for Biotecbnology Information (NCBI) Taxonomy website: http://www 3 .ncbi.nlm.nih.gov/Taxonomy/).
  • This reaction may be also catalyzed by a kinase, e.g., glycerol kinase.
  • a kinase e.g., glycerol kinase.
  • NBI National Center for Biotechnology Information
  • Lactate secretion can also be avoided by deregulation, e.g., knockout, of lactate dehydrogenase. Since glycerol and lactate formation could be important for NADH regeneration, negative effects on the overall performance of the organism can however not be excluded. In case carbon flux through the lower glycolytic chain is limited by the capacity of glyceraldehyde 3-phosphate dehydrogenase as previously speculated (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Cocaign-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem.
  • deregulation of one or more of the above genes in combination is useful in the production of a fine chemical, e.g., lysine.
  • sucrose is also useful as carbon source for lysine production by C. glutamicum, e.g., used in conjunction with the methods of the invention.
  • Sucrose is the major carbon source in molasses.
  • the fructose unit of sucrose enters glycolysis at the level of fructose 1,6-bisphosphatase (Dominguez, H. and N. D. Lindley. 1996. Appl. Environ. Microbiol. 62:3878-3880). Therefore this part of the sucrose molecule—assuming an inactive fructose 1,6-bisphosphatase—probably does not enter into the PPP, so that NADPH supply in lysine producing strains could be limited.
  • the first step of strain construction calls for an allelic replacement of the lysC wild-type gene in C. glutamicum ATCC13032.
  • a nucleotide replacement in the lysC gene is carried out, so that, the resulting protein, the amino acid Thr in position 311 is replaced by an Ile.
  • lysC is amplified by use of the Pfu Turbo PCR system (Stratagene USA) in accordance with the instructions of the manufacturer.
  • Chromosomal DNA from C. glutamicum ATCC13031 is prepared according to Tauch et al.
  • the amplified fragment is flanked at its 5′ end by a SalI restriction cut and at its 3′ end by aMluI restriction cut. Prior to the cloning, the amplified fragment is digested by these two restriction enzymes and purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg).
  • the obtained polynucleotide is cloned through the SalI and MluI restriction cuts in pCLIK5 MCS with integrated SacB, referred to in the following as pCIS (SEQ ID NO:5) and transformed in E. coli XL-1 blue.
  • pCIS SEQ ID NO:5
  • a selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 ⁇ g/mL)—containing LB agar (Lennox, 1955, Virology, 1:190).
  • the plasmid is isolated and the expected nucleotide sequence is confirmed by sequencing.
  • the preparation of the plasmid DNA is carried out according to methods of and using materials of the company Quiagen. Sequencing reactions are carried out according to Sanger et al.
  • the targeted mutagenesis of the lysC gene from C. glutamicum is carried out using the QuickChange Kit (Company: Stratagene/USA) in accordance with the instructions of the manufacturer.
  • the mutagenesis is carried out in the plasmid pCIS lysC, SEQ ID NO:6.
  • the following oligonucleotide, primers are synthesized for the replacement of thr 311 by 311 ile by use of the QuickChange method (Stratagene):
  • the plasnid pCIS lysC thr311 ile is transformed in C. glutamicum ATCC13632 by means of electroporation, as described in Liebl, et al. (1989) FEMS. Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870.
  • the chromosomal arrangement of the lysC locus of individual transformants is checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor. It is thereby established that the transformants involved are those that have integrated the transformed plasmid by homologous recombination at the lysC locus.
  • the cells are plated out on a saccharose CM agar medium (10% saccharose) and incubated at 30° C. for 24 hours. Because the sacB gene contained in the vectbr pCIS ilysC thr311ile converts saccharose into a toxic product, only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type lysC gene and the mutated gene lysC thr311ile. During the homologous recombination, either the wild-type gene or the mutated gene together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.
  • Clones with deleted SacB gene must simultaneously show kanamycin-sensitive growth behavior.
  • Such kanamycin-sensitive clones are investigated in a shaking flask for their lysine productivity (see Example 6).
  • the non-treated C. glutamicum ATCC13032 is taken.
  • Clones with an elevated lysine production in comparison to the control are selected, chromosomal DNA are recovered, and the corresponding region of the lysC gene is amplified by a PCR reaction and sequenced.
  • One such clone with the property of elevated lysine synthesis and detected mutation in lysC at position 932 is designated as ATCC13032 lysCfbr.
  • Chromosomal DNA from C. glutamicum ATCC13032 is prepared according to Tauch et al. (1995) Plasmid 33:168-179 or Eikmanns et al. (1994) Microbiology 140:1817-1828.
  • PCR 1 With the oligonucleotide primers SEQ ID NO 11 and SEQ ID NO 12, the chromos 6 mal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), a region lying upstream of the start codon of the elongation factor TU is amplified by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • the obtained DNA fragment of approximately 200 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 2 With the oligonucleotide primers SEQ ID NO 13 and SEQ ID NO 14, the chromosomal DNA as template, and Pfu Turbo polymerase. (Company: Stratagene); the 5′ region of the gene for fructose-1,6-bisphosphatase is amplified by use of the, polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • SEQ ID NO 13 5′-GAAGTCCAGGAGGACATACAATGAACCTAAAGAACCCCGA-3′ and SEQ ID NO 14 5′-ATCTACGTCGACCCAGGATGCCCTGGATTTC-3′
  • the obtained DNA fragment of approximately 740 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 3 With the oligonucleotide primers SEQ ID NO 15 and SEQ ID NO 16, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), a region lying upstream of the start codon of fructose-1,6-bisphosphatase is amplified by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • SEQ ID NO 15 5′-TATCAACGCGTTCTTCATCGGTAGCAGCACC-3′ and SEQ ID NO 16 5′-CATTCGCAGGGTAACGGCCACTGAAGGGCCTCCTGGG-3′
  • the obtained DNA fragment of approximately 720 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 4 With the oligonucleotide primers SEQ ID NO 17 and SEQ ID NO 14, the PCR products from PCR 1 and 2 as template, and Pfu Turbo polymerase (Company: Stratagene), a fusion PCR is carried out by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • the obtained DNA fragment of approximately 920 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 5 With the oligonucledtide primers SEQ ID NO 15 and SEQ ID NO 14, the PCR products from PCR 3 and 4 as template, and Pfu Turbo polymerase (Company: Stratagene), a fuision PCR is carried out by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • the obtained DNA fragment of approximately 1640 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer. Following this, it is cleaved using the restriction enzymes MluI and SalI (Roche Diagnostics, Mannheim) and the DNA fragment is purified using the GFXTM PCR DNA and Gel Band Purification Kit.
  • the vector pCIS is cut with the restriction enzymes MluI and SalI and a fragment of 4.3 kb size is isolated, after electrophoretic separation, by use of the GFXTM PCR DNA and Gel Band Purification Kit.
  • the vector fragment is ligated together with the PCR fragment from PCR 5 by use of the Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer and the ligation batch is transformed in competent E. coli XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)).
  • a selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 ⁇ g/mL)—containing LB agar (Lennox, 1955, Virology, 1:190).
  • the preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied Biosystems, Rothstadt) and analyzed.
  • the resulting plasmid pCIS Peftu fructose-1,6-bisphosphatase is listed as SEQ ID NO:17.
  • the plasmid pCIS Peftu fructose-1,6-bisphosphatase is transformed in C. glutamicum ATCC13032 lysCfbr by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the fructose-1,6-bisphosphatase gene locus of individual transformants is checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory-Manual, Crold Spring Harbor.
  • the transformants involve those that have integrated the transformed plasmid by homologous recombination at the fructose-1,6-bisphosphatase gene locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a saccharose CM agar medium (10% saccharose) and incubated at 30° C. for 24 hours.
  • Peftu fructose-1,6-bisphosphatase converts saccharose into a toxic product
  • only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type fructose-1,6-bisphosphatase gene and the Peftu fructose-1,6-bisphosphatase fusion.
  • the homologous recombination either the wild-type gene or the fusion together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.
  • oligonucleotides that are homologous to the Peftu promoter and to the fructose-1,6-bisphosphatase gene.
  • the PCR conditions are selected as follows: initial denaturation: 5 min at 95° C.; denaturation 30 sec at 95° C.; hybridization 30 sec at 55° C.; amplification 2 min at 72° C.; 30 cycles; end extension 5 min at 72° C.
  • no PCR product could form owing to the selection of the oligonucleotide.
  • Only for clones that had completed the replacement of the natural promoter by Peftu through the 2nd recombination are a band with a size of 340 bp expected. Overall, of the tested clones, 2 clones are positive.
  • the clones are designated as ATCC13032 lysCfbr Peftu fructose-1,6-bisphosphatasel 1 and 2.
  • Peftu fructose-1,6-bisphosphatase 1 are cultivated on CM plates (10.0 g/L D-glucose, 2.5 g/L NaCl, 2.0 g/L urea, 10.0 g/L bacto pepton (Difco), 5.0 g/L yeast extract (Difco), 5.0 g/L beef extract (Difco), 22.0 g/L agar (Difco), autoclaved (20 min.
  • vitamin B12 hydroxycobalamin Sigma Chemicals
  • a stock solution 200 ⁇ g/mL, sterile-filtered
  • a final concentration of 100 ⁇ g/L is added up to a final concentration of 100 ⁇ g/L.
  • the determination of the amino acid concentration is conducted by means of high pressure liquid chromatography according to Agilent on an Agilent 1100 Series LC System HPLC.
  • a precolumn derivatization with ortho-phthalaldehyde permits the quantification of the amino acids that are formed; the separation of the amino acid mixture takes place on a Hypersil AA columnn (Agilent).
  • Chromosomal DNA from C. glutamicum ATCC 13032 is prepared according to Tauch et al. (1995) Plasmid 33:168-179 or Eikanns et al. (1994) Microbiology 140:1817-1828.
  • PCR 1 With the oligonucleotide primers SEQ ID NO 18 and SEQ ID NO 19, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), a region lying upstream of the start codon of the superoxid dismutase is amplified by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • the obtained DNA fragment of approximately 200 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 2 With the oligonucleotide primers SEQ ID NO 20 and SEQ ID NO 21, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), the 5′ region of the gene for fructose-1,6-bisphosphatase is amplified by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • SEQ ID NO 20 5′-CCCGGAATAATTGGCAGCTACTGAAGGGCCTCCTGGG-3′ and SEQ ID NO 21 5′-TATCAACGCGTTCTTCATCGGTAGCAGCACC-3′
  • the obtained DNA fragment of approximately 720 bp size is purified usig the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 3 With the oligonucleotide primers SEQ ID NO 22 and SEQ ID NO 23, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), a region lying upstream of the start codon of fructose-1,6-bisphosphatase is amplified by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • SEQ ID NO 22 5′-TACGAAAGGATTTTTTACCCATGAACCTAAAGAACCCCGA-3′ and SEQ ID NO 23 5′-ATCTACGTCGACCCAGGATGCCCTGGATTTC-3′
  • the obtained DNA fragment of approximately 740 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR 4 With the oligonucleotide primers SEQ ID NO 18 and SEQ ID NO 23, the PCR products from PCR 1 and 3 as template, and Pfu Turbo polymerase (Company: Stratagene), a fusion PCR is carried out by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press. The obtained DNA fragment of approximately 930 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer.
  • PCR polymerase chain reaction
  • PCR 5 With the oligonucleotide primers SEQ ID NO 21 and SEQ ID NO 23, the PCR products from PCR 2 and 4 as template, and Pfu Turbo polymerase (Company: Stratagene), a fusion PCR is carried out by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.
  • PCR polymerase chain reaction
  • the obtained DNA fragment of approximately 1650 bp size is purified using the GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer. Following this, it is cleaved using the restriction enzymes MluI and SalI (Roche Diagnostics, Mannheim) and the DNA fragment is purified using the GFXTM PCR DNA and Gel Band Purification Kit.
  • the vector pCIS is cut with the restriction enzymes MluI and SalI and a fragment of 4.3 kb size is isolated, after elecfrophoretic separation, by use of the GFXTM PCR DNA and Gel Band Purification Kit.
  • the vector fragment is ligated together with the PCR fragment from PCR 5 by use of the Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer and the ligation batch is transformed in competent E. coli XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et.al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)).
  • a selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 ⁇ g/mL)—containing LB agar (Lennox, 1955, Virology, 1:190).
  • the preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied Biosystems, Rothstadt) and analyzed.
  • the resulting plasmid pCIS Psod fructose-1,6-bisphosphatase is listed as SEQ ID NO: 24.
  • the plasmid pCIS Psod fructose-1,6-bisphosphatase is transformed in C. glutamicum ATCC13032 lysCfbr by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the fructose-1,6-bisphosphatase gene locus of individual transformants is checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor.
  • the transformants involve those that have integrated the transformed plasmid by homologous recombination at the fructose-1,6-bisphosphatase gene locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a saccharose CM agar medium (10% saccharose) and incubated at 30° C. for 24 hours.
  • the sacB gene contained in the vector pCIS Psod fructose-1,6-bisphosphatase converts saccharose into a toxic product
  • only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type fructose-1,6-bisphosphatase gene and the Psod fructose-1,6-bisphosphatase fusion.
  • the homologous recombination either the wild-type gene or the fusion together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.
  • oligonucleotides that are homologous to the Psod promoter and to the fructose-1,6-bisphosphatase gene.
  • the PCR conditions are selected as follows: initial denaturation: 5 min at 95° C.; denaturation 30 sec it 95° C.; hybridization 30 sec at 55° C.; amplification 2 min at 72° C.; 30 cycles; end extension 5 min at 72° C.
  • no PCR product could form owing to the selection of the oligonucleotide.
  • Only three clones that had completed the replacement of the natural promoter by Psod through the 2nd recombination are a band with a size of 350 bp expected. Overall, of the tested clones, 3 clones are positive.
  • the clones are designated as ATCC13032 lyscfbr Psod fructose-1,6-bisphosphatase 1, 2 and 3.
  • the strains ATCC13032, ATCC13032 lysCfbr, and ATCC13032 lysCfbr Psod fructose-1,6-bisphosphatase 1 are cultivated on CM plates (10.0 g/L D-glucose, 2.5 g/L NaCl, 2.0 g/L urea, 10.0 g/L bacto pepton (Difco), 5.0 g/L yeast extract (Difco), 5.0 g/L beef extract (Difco), 22.0 g/L agar (Difco), autoclaved (20 min.
  • vitamin B12 (hydroxycobalani Sigma Chemicals) from a stock solution (200 ⁇ g/mL, sterile-filtered) is added up to a final concentration of 100 ⁇ g/L.
  • the determination of the amino acid concentration is conducted by means of high pressure liquid chromatography according to Agilent on an Agilent 1100 Series LC System HPLC.
  • a precolumn derivatization with ortho-phthalaldehyde permits the quantification of the amino acids that are formed; the separation of the amino acid mixture takes place on a Hypersil AA column (Agilent).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
US10/579,690 2003-12-18 2004-12-17 Method for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum Abandoned US20080032374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB0306456 2003-12-18
IBIB2003/006456 2003-12-18
PCT/IB2004/004429 WO2005059139A2 (en) 2003-12-18 2004-12-17 Methods for the preparation of lysine by fermentation of corynebacterium glutamicum

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/004429 A-371-Of-International WO2005059139A2 (en) 2003-12-18 2004-12-17 Methods for the preparation of lysine by fermentation of corynebacterium glutamicum

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/021,081 Division US20080160585A1 (en) 2003-12-18 2008-01-28 Methods for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum

Publications (1)

Publication Number Publication Date
US20080032374A1 true US20080032374A1 (en) 2008-02-07

Family

ID=34685565

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/579,690 Abandoned US20080032374A1 (en) 2003-12-18 2004-12-17 Method for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum
US12/021,081 Abandoned US20080160585A1 (en) 2003-12-18 2008-01-28 Methods for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum
US12/533,677 Expired - Fee Related US8048651B2 (en) 2003-12-18 2009-07-31 Methods for the preparation of lysine by fermentation of Corynebacterium glutamicum

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/021,081 Abandoned US20080160585A1 (en) 2003-12-18 2008-01-28 Methods for the Preparation of Lysine by Fermentation of Corynebacterium Glutamicum
US12/533,677 Expired - Fee Related US8048651B2 (en) 2003-12-18 2009-07-31 Methods for the preparation of lysine by fermentation of Corynebacterium glutamicum

Country Status (15)

Country Link
US (3) US20080032374A1 (enrdf_load_stackoverflow)
EP (2) EP1697518A2 (enrdf_load_stackoverflow)
JP (2) JP2007514437A (enrdf_load_stackoverflow)
KR (1) KR20060125804A (enrdf_load_stackoverflow)
CN (2) CN1890372A (enrdf_load_stackoverflow)
AR (1) AR047153A1 (enrdf_load_stackoverflow)
AU (1) AU2004299729A1 (enrdf_load_stackoverflow)
BR (1) BRPI0417772A (enrdf_load_stackoverflow)
CA (1) CA2547860A1 (enrdf_load_stackoverflow)
IN (2) IN2006CH02603A (enrdf_load_stackoverflow)
MX (1) MXPA06006759A (enrdf_load_stackoverflow)
NO (1) NO20062494L (enrdf_load_stackoverflow)
RU (1) RU2006125500A (enrdf_load_stackoverflow)
TW (1) TW200533745A (enrdf_load_stackoverflow)
WO (1) WO2005059139A2 (enrdf_load_stackoverflow)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318287A1 (en) * 2005-11-28 2008-12-25 Matthias Boy Fermentative Production of Organic Compounds Using Substances Containing Dextrin
US20100330635A1 (en) * 2009-04-30 2010-12-30 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US20110129904A1 (en) * 2009-12-10 2011-06-02 Burgard Anthony P Methods and organisms for converting synthesis gas or other gaseous carbon sources and methanol to 1,3-butanediol
WO2011158975A1 (en) * 2010-06-15 2011-12-22 Paik Kwang Industrial Co., Ltd. Production process for amino acids of the aspartate family using microorganisms
US9796991B2 (en) 2014-02-14 2017-10-24 Institute Of Microbiology, Chinese Academy Of Sciences Recombinant strain producing L-amino acids, constructing method therefor and method for producing L-amino acids
US10188722B2 (en) 2008-09-18 2019-01-29 Aviex Technologies Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN115490761A (zh) * 2021-11-01 2022-12-20 中国科学院天津工业生物技术研究所 基于赖氨酸外排蛋白构建的重组微生物及生产赖氨酸的方法
CN116411009A (zh) * 2021-12-31 2023-07-11 上海凯赛生物技术股份有限公司 用于制备l-赖氨酸的表达盒、基因工程菌及其应用
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10359594A1 (de) * 2003-12-18 2005-07-28 Basf Ag PEF-TU-Expressionseinheiten
EP1584680A1 (en) * 2004-04-08 2005-10-12 Boehringer Ingelheim Austria GmbH Fed-batch fermentation process for the production of plasmid DNA
EP1996714A1 (en) * 2006-03-09 2008-12-03 Basf Se PROCESS FOR THE PRODUCTION OF ß-LYSINE
AU2008308827B2 (en) * 2007-10-05 2011-02-17 3M Innovative Properties Company Organic chemical sensor comprising plasma-deposited microporous layer, and method of making and using
KR100964078B1 (ko) 2008-03-05 2010-06-16 씨제이제일제당 (주) 5'-이노신산 생산능이 향상된 코리네박테리움암모니아게네스 및 그를 이용한 5'-이노신산 생산 방법
EP3351619A1 (en) * 2008-03-27 2018-07-25 Genomatica, Inc. Microorganisms for the production of adipic acid and other compounds
CN102753682A (zh) 2009-12-17 2012-10-24 巴斯夫欧洲公司 用于生产尸胺的方法和重组微生物
WO2011116279A2 (en) * 2010-03-18 2011-09-22 William Marsh Rice University Bacteria and method for synthesizing fatty acids
DE102010019059A1 (de) * 2010-05-03 2011-11-03 Forschungszentrum Jülich GmbH Sensoren zur intrazellulären Metabolit-Detektion
RU2486248C2 (ru) * 2011-06-29 2013-06-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет инженерной экологии" (ФГБОУ ВПО "МГУИЭ") Способ биосинтеза l-лизина
KR20140084202A (ko) 2011-10-17 2014-07-04 윌리엄 마쉬 라이스 유니버시티 지방산의 합성을 위한 박테리아 및 방법
EP2971023B1 (en) * 2013-03-15 2024-12-11 Kiverdi, Inc. Methods of using natural and engineered organisms to produce small molecules for industrial application
KR101621243B1 (ko) 2014-08-28 2016-05-16 씨제이제일제당 주식회사 L-라이신 생산능을 갖는 코리네박테리움 미생물 및 이를 이용한 l-라이신 생산 방법
WO2016090164A1 (en) * 2014-12-03 2016-06-09 Fenner U.S., Inc. Improved filament for fused deposit modeling
CN106190939B (zh) * 2016-07-18 2020-04-07 清华大学 高产透明质酸的重组谷氨酸棒杆菌及其制备方法与应用
WO2018040469A1 (zh) 2016-09-01 2018-03-08 宁夏伊品生物科技股份有限公司 发酵生产l-赖氨酸的棒杆菌
CN109536431A (zh) * 2018-12-04 2019-03-29 江苏省农业科学院 复合生化复苏因子组合物及其应用
KR102147776B1 (ko) 2019-09-20 2020-08-26 대상 주식회사 L-라이신 생산능력이 향상된 코리네박테리움속 미생물 및 이를 이용한 라이신의 생산 방법
CN111471693B (zh) * 2019-11-27 2022-04-01 内蒙古伊品生物科技有限公司 一种产赖氨酸的谷氨酸棒杆菌及其构建方法与应用
CN113136382B (zh) * 2020-01-19 2023-01-31 河北科技大学 基于CRISPRi调控的利用谷氨酸棒状杆菌合成乙醛酸的方法
EP4332230A4 (en) * 2021-04-30 2025-06-25 CJ Cheiljedang Corporation CORYNEBACTERIUM GLUTAMICUM VARIANT WITH IMPROVED L-LYSINE PRODUCTION CAPACITY AND METHOD FOR PRODUCING L-LYSINE THEREOF
CN113736761B (zh) * 2021-08-18 2023-06-27 新发药业有限公司 Rna解旋酶突变体、突变基因及其在制备维生素b2中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529026T2 (de) 1994-07-19 2003-07-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Trehalose, ihre Herstellung und ihre Verwendung
KR100878336B1 (ko) * 1999-06-25 2009-01-14 백광산업 주식회사 탄소 대사 및 에너지 생산과 관련된 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
KR20070087035A (ko) 1999-06-25 2007-08-27 바스프 악티엔게젤샤프트 대사 경로 단백질을 코딩하는 코리네박테리움 글루타미쿰유전자
CA2377693C (en) 1999-07-23 2016-11-08 Archer-Daniels-Midland Company Methods for producing l-amino acids
US6586214B1 (en) * 1999-09-15 2003-07-01 Degussa Ag Method for increasing the metabolic flux through the pentose phosphate cycle in coryneform bacteria by regulation of the phosphoglucose isomerase (pgi gene)
DE19956686A1 (de) 1999-11-25 2001-05-31 Degussa Neue für die Gene sucC und sucD codierende Nukleotidsequenzen
JP4623825B2 (ja) * 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
DE10046870A1 (de) 2000-09-20 2002-03-28 Basf Ag Verfahren zur Veränderung des Genoms von Corynebakterien
US7049106B2 (en) * 2001-04-10 2006-05-23 Degussa Ag Process for the production of L-amino acids by fermentation using coryneform bacteria with an attenuated mqo gene
US20090158452A1 (en) * 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
JPWO2004089996A1 (ja) 2003-04-04 2006-07-06 綜研化学株式会社 変性シクロオレフィンコポリマー、その製造方法及びそのポリマーの用途

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318287A1 (en) * 2005-11-28 2008-12-25 Matthias Boy Fermentative Production of Organic Compounds Using Substances Containing Dextrin
US8728773B2 (en) * 2005-11-28 2014-05-20 Matthias Boy Fermentative production of organic compounds using substances containing dextrin
US10188722B2 (en) 2008-09-18 2019-01-29 Aviex Technologies Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment
US9017983B2 (en) 2009-04-30 2015-04-28 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US20100330635A1 (en) * 2009-04-30 2010-12-30 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US11180780B2 (en) 2009-04-30 2021-11-23 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US9708632B2 (en) 2009-04-30 2017-07-18 Genomatica, Inc. Organisms for the production of 1,3-butanediol
US8268607B2 (en) 2009-12-10 2012-09-18 Genomatica, Inc. Methods and organisms for converting synthesis gas or other gaseous carbon sources and methanol to 1,3-butanediol
US20110129904A1 (en) * 2009-12-10 2011-06-02 Burgard Anthony P Methods and organisms for converting synthesis gas or other gaseous carbon sources and methanol to 1,3-butanediol
KR101512432B1 (ko) 2010-06-15 2015-04-16 백광산업 주식회사 미생물을 이용한 아스파테이트 계열 아미노산의 생산방법
RU2535973C2 (ru) * 2010-06-15 2014-12-20 Пайк Кванг Индастриал Ко., Лтд. Способ продуцирования аминокислот семейства аспартата с использованием микроорганизмов
WO2011158975A1 (en) * 2010-06-15 2011-12-22 Paik Kwang Industrial Co., Ltd. Production process for amino acids of the aspartate family using microorganisms
US9796991B2 (en) 2014-02-14 2017-10-24 Institute Of Microbiology, Chinese Academy Of Sciences Recombinant strain producing L-amino acids, constructing method therefor and method for producing L-amino acids
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN115490761A (zh) * 2021-11-01 2022-12-20 中国科学院天津工业生物技术研究所 基于赖氨酸外排蛋白构建的重组微生物及生产赖氨酸的方法
CN116411009A (zh) * 2021-12-31 2023-07-11 上海凯赛生物技术股份有限公司 用于制备l-赖氨酸的表达盒、基因工程菌及其应用

Also Published As

Publication number Publication date
EP1939296A2 (en) 2008-07-02
RU2006125500A (ru) 2008-01-27
IN2006CH02603A (enrdf_load_stackoverflow) 2007-06-08
CA2547860A1 (en) 2005-06-30
US20100015674A1 (en) 2010-01-21
BRPI0417772A (pt) 2007-04-17
AR047153A1 (es) 2006-01-11
EP1697518A2 (en) 2006-09-06
US20080160585A1 (en) 2008-07-03
CN1890372A (zh) 2007-01-03
JP2007514437A (ja) 2007-06-07
AU2004299729A1 (en) 2005-06-30
NO20062494L (no) 2006-09-06
IN2008CH00387A (enrdf_load_stackoverflow) 2008-09-19
TW200533745A (en) 2005-10-16
JP4903742B2 (ja) 2012-03-28
CN101230355A (zh) 2008-07-30
MXPA06006759A (es) 2006-09-04
US8048651B2 (en) 2011-11-01
JP2008259505A (ja) 2008-10-30
WO2005059139A3 (en) 2005-08-11
EP1939296A3 (en) 2010-08-25
KR20060125804A (ko) 2006-12-06
WO2005059139A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
US8048651B2 (en) Methods for the preparation of lysine by fermentation of Corynebacterium glutamicum
US20080038787A1 (en) Methods for the Preparation of a Fine Chemical by Fermentation
RU2571932C2 (ru) Способ получения l-орнитина с использованием бактерий, сверхэкспрессирующих lyse
JP5710096B2 (ja) Ｐｅｆ−ｔｓ発現ユニット
US20070134768A1 (en) Methods for the preparation of a fine chemical by fermentation
JP2008237218A (ja) Ｐｇｒｏ発現ユニット
US7355029B2 (en) Genes encoding carbon metabolism and energy-producing proteins
EP1444343A2 (de) Gene die für stoffwechselweg-proteine codieren
US20150118720A1 (en) Process for producing amino acid
EP1444352A2 (de) Gene, die für dna-replikations- und pathogenese proteine codieren
ZA200404420B (en) Genes coding for pohspoenolpyruvate-sugar-phosphotransferase proteins

Legal Events

Date Code Title Description
AS Assignment

Owner name: BASF AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZELDER, OSKAR;KLOPPROGGE, CORINNA;SCHRODER, HARTWIG;AND OTHERS;REEL/FRAME:018993/0887;SIGNING DATES FROM 20060831 TO 20060918

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION